Eye Diseases Terminated Phase 2 Trials for Ranibizumab (DB01270)

IndicationStatusPhase
DBCOND0030511 (Eye Diseases)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02348359X-82 to Treat Age-related Macular DegenerationTreatment